Should cholesterol-lowering medications be available in Canada without a prescription?

Canadian Journal of Cardiology

Volumn 23, Issue 3, 2007, Pages 189-193

  Rashid, Shirya ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cardiovascular disease; Cholesterol; HMG CoA reductase inhibitor; Lipid; Statin

Indexed keywords

ALPHA TOCOPHEROL; GARLIC EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NON PRESCRIPTION DRUG; NUTRACEUTICAL; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; ZOCOR HEART PRO;

CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONSULTATION; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HEALTH CARE SYSTEM; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; MYOPATHY; MYOSITIS; NAUSEA; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY PREVENTION; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; BLOOD; DRUG EFFECT;

ANTICHOLESTEREMIC AGENTS; CANADA; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUGS, NON-PRESCRIPTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRESCRIPTIONS, DRUG;

EID: 34247282030     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70742-0     Document Type: Article

References (26)

1. The Growing Burden of Heart Disease and Stroke in Canada, 2003. Heart and Stroke Foundation Canada. (Version current at October 19, 2006).
2. Pearson TA. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am J Cardiol 2004;94:4F-8F.
3. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on cardiovascular disease prevention. Circulation 2000;102:3137-47.
4. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993;269:3002-8.
5. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: Findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003;107:2185-9.
6. Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: Findings from the National Health and Nutrition Examination Survey 111. J Am Coll Cardiol 2004;43:1791-6.
7. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169:921-4. (Erratum in 2003:169;1149).
8. Roberts WC. Over-the-counter statin drug. Am J Cardiol 2004;94:1362.
9. Pieper RM, Arnett DK, McGovern PG, Shahar E, Blackburn H, Luepker RV. Trends in cholesterol knowledge and screening and hypercholesterolemia awareness and treatment, 1980-1992. The Minnesota Heart Survey. Arch Intern Med 1997;157:2326-32.
10. Hendrix KH, Riehle JE, Egan BM. Ethnic, gender, and age-related differences in treatment and control of dyslipidemia in hypertensive patients. Ethn Dis 2005;15:11-6.
11. Wharry S, Sibbald B. What physician shortage? CMAJ 2002;167:64.
12. Nash DB, Nash SA. Reclassification of simvastatin to over-the-counter status in the United Kingdom: A primary prevention strategy. Am J Cardiol 2004;94:35F-39F.
13. Strom BL. Statins and over-the-counter availability. N Engl J Med 2005;352:1403-5.
14. Brass EP. Consumer behavior in the setting of over-the-counter statin availability: Lessons from the consumer use study of OTC Mevacor. Am J Cardiol 2004;94:22F-29F.
15. Gotto AM Jr. Over-the-counter statins and cardiovascular disease prevention: Perspectives, challenges, and opportunities. Clin Pharmacol Ther 2005;78:213-7.
16. Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001;345:810-6.
17. Melin JM, Struble WE, Tipping RW, et al. A Consumer Use Study of Over-The-Counter lovastatin (CUSTOM). Am J Cardiol 2004;94:1243-8.
18. Cohen JD. A population-based approach to cholesterol control. Am J Med 1997;102:23-5.
19. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disase? Br Med J 1994;308:367-72.
20. Gossel TA. Implications of the reclassification of drugs from prescription-only to over-the-counter status. Clin Ther 1991;13:200-15.
21. McKenney JM, Brown WV, Cohen JD, Cahill E. The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: Is this a good idea? Am J Cardiol 2004;94:16F-21F.
22. Smith SC, Jr. Bridging the treatment gap. Am J Cardiol 2000;85:3E-7E.
23. Carlsten A, Wennberg M, Bergendal L. The influence of Rx-to-OTC changes on drug sales. Experiences from Sweden 1980-1994. Clin Pharm Ther 1996;21:423-30. (Erratum in 1997;22:155-6).
24. Abrams J. Over-the-counter statins: A new controversy. Nat Clin Pract Cardiovasc Med 2005;2:174-5.
25. Francis SA, Barnett N, Denham M. Switching of prescription Drugs to over-the-counter status: Is it a good thing for the elderly? Drugs Aging 2005;22:361-70.
26. Richards MK, Blumenfield S, Lyon RA. Managed care market perspectives on the over-the-counter availability of statins. J Manag Care Pharm 2004;10:543-50.